INT103327

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.71
First Reported 2002
Last Reported 2010
Negated 1
Speculated 2
Reported most in Body
Documents 45
Total Number 65
Disease Relevance 32.50
Pain Relevance 2.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (F8) oxidoreductase activity (F8) extracellular region (F8)
cell adhesion (F8) plasma membrane (F8)
Anatomy Link Frequency
plasma 11
platelets 4
pericytes 3
smooth muscle cells 3
ovaries 3
F8 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 39 99.16 Very High Very High Very High
cva 186 97.16 Very High Very High Very High
abdominal pain 20 88.76 High High
Angina 20 82.04 Quite High
pruritus 34 78.76 Quite High
headache 37 77.12 Quite High
Pain 29 75.84 Quite High
Potency 34 72.00 Quite High
medulla 22 66.08 Quite High
Central nervous system 5 60.92 Quite High
Disease Link Frequency Relevance Heat
Coagulation Disorder 1999 100.00 Very High Very High Very High
Hemorrhage 1182 99.82 Very High Very High Very High
Injury 182 99.80 Very High Very High Very High
Disease 168 99.76 Very High Very High Very High
INFLAMMATION 40 99.52 Very High Very High Very High
Cv Unclassified Under Development 6 98.20 Very High Very High Very High
Cv General 3 Under Development 17 97.16 Very High Very High Very High
Osteoarthritis 30 96.48 Very High Very High Very High
Arthropathy 135 96.24 Very High Very High Very High
Thrombosis 33 95.60 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In this article we present a new platform technology that produces long-acting forms of FVIII and FVIIa and improves the efficacy of hemophilia treatment.
Gene_expression (produces) of FVIII associated with coagulation disorder
1) Confidence 0.71 Published 2010 Journal Int J Nanomedicine Section Abstract Doc Link PMC2939703 Disease Relevance 0.40 Pain Relevance 0
Accordingly, expression of FVIII in platelets was shown to be effective at inducing hemostasis even when FVIII protein expression levels did not exceed 1% of normal levels.
Gene_expression (expression) of FVIII in platelets
2) Confidence 0.71 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.55 Pain Relevance 0
Accordingly, expression of FVIII in platelets was shown to be effective at inducing hemostasis even when FVIII protein expression levels did not exceed 1% of normal levels.
Gene_expression (expression) of FVIII in platelets
3) Confidence 0.71 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.54 Pain Relevance 0
Swedish patients monitored longitudinally provided evidence that early prophylaxis aimed to produce FVIII trough levels above 0.01 U/mL translates into improved outcome.
Gene_expression (produce) of FVIII
4) Confidence 0.68 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835555 Disease Relevance 0.97 Pain Relevance 0.03
To attain consistent and stable production of rFVIII, a continuous (chemostat) perfusion bioreactor culture is used to harvest the clotting factor with minimal environmental changes to the cell line.
Gene_expression (production) of rFVIII associated with coagulation disorder
5) Confidence 0.68 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291300 Disease Relevance 0.10 Pain Relevance 0
Factor VIII products
Gene_expression (products) of Factor VIII
6) Confidence 0.67 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835555 Disease Relevance 0.82 Pain Relevance 0.09
Earlier cohort studies suggested an inverse relationship between the age at first exposure and the probability of inhibitor development.71,72 Later studies with multivariate analyses adjusted for other variables including family history of inhibitor development as well as FVIII gene mutation did not confirm these results.73,74 To the contrary, children starting prophylaxis before the age of three years experienced a 70% reduction in the risk of inhibitor development.73
Gene_expression (mutation) of FVIII gene
7) Confidence 0.67 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835555 Disease Relevance 0.26 Pain Relevance 0.03
To this end, the National Hemophilia Foundation Medical and Scientific Advisory Council (MASAC) also recommended recombinant FVIII products as the treatment of choice for patients with hemophilia A (MASAC #177 2006).
Gene_expression (products) of FVIII associated with coagulation disorder
8) Confidence 0.67 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291300 Disease Relevance 0.70 Pain Relevance 0
With infusion of factor VIII (FVIII), development of an anamnestic response and possible appearance of high-titre inhibitor remains a valid concern.
Gene_expression (infusion) of FVIII
9) Confidence 0.67 Published 2003 Journal Haemophilia Section Abstract Doc Link 12558792 Disease Relevance 0.72 Pain Relevance 0.06
The dosage of FVIII concentrate should be adjusted depending on plasma FVIII levels and bleeding symptoms [2].
Gene_expression (levels) of FVIII in plasma associated with hemorrhage
10) Confidence 0.67 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2918632 Disease Relevance 0.75 Pain Relevance 0.06
By directly activating FX on the surface of activated platelets at the site of injury (thereby bypassing FVIII and FIX), rFVIIa can circumvent the actions of inhibitory antibodies present in patients with acquired hemophilia [2].
Gene_expression (bypassing) of FVIII in platelets associated with coagulation disorder and injury
11) Confidence 0.67 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2918632 Disease Relevance 0.79 Pain Relevance 0
In this study, we designed an hGH-loaded dex-HEMA microsphere formulation which releases the protein for 7 days.
Gene_expression (dex) of HEMA
12) Confidence 0.65 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0.08 Pain Relevance 0
The FVIII used to treat hemophilia A may be produced in mammalian cell lines genetically engineered to synthesize human FVIII (recombinant FVIII, rFVIII) or may be purified from normal pooled plasma (plasma-derived FVIII, pdFVIII).8
Gene_expression (synthesize) of FVIII in plasma associated with coagulation disorder
13) Confidence 0.62 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 1.03 Pain Relevance 0.12
FVIII is a large glycoprotein (2332 amino acids) that is synthesized as a 330 kDa precursor and undergoes multiple processing steps to yield a heterodimer composed of a light chain (80 kDa) and a heterogeneous heavy chain (90–210 kDa)9 FVIII circulates in the plasma as an inactive precursor, tightly complexed with von Willebrand factor (vWF).
Gene_expression (synthesized) of FVIII in plasma
14) Confidence 0.62 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.86 Pain Relevance 0.04
The FVIII used to treat hemophilia A may be produced in mammalian cell lines genetically engineered to synthesize human FVIII (recombinant FVIII, rFVIII) or may be purified from normal pooled plasma (plasma-derived FVIII, pdFVIII).8
Gene_expression (synthesize) of FVIII in plasma associated with coagulation disorder
15) Confidence 0.62 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 1.03 Pain Relevance 0.12
The FVIII used to treat hemophilia A may be produced in mammalian cell lines genetically engineered to synthesize human FVIII (recombinant FVIII, rFVIII) or may be purified from normal pooled plasma (plasma-derived FVIII, pdFVIII).8
Gene_expression (produced) of FVIII in plasma associated with coagulation disorder
16) Confidence 0.62 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 1.13 Pain Relevance 0.15
Standard FVIII was administered in the first study segment whereas PEGLip-FVIII was provided in the second and third segments.
Gene_expression (provided) of PEGLip-FVIII
17) Confidence 0.62 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.55 Pain Relevance 0
Development of modified forms of FVIII is still in the preclinical stage and the safety and efficacy of these approaches has yet to be demonstrated in humans.28
Gene_expression (forms) of FVIII
18) Confidence 0.62 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.46 Pain Relevance 0
In the years to come, we expect PEGLip-FVIII and PEGLip-FVIIa to become an attractive treatment for hemophilia A patients and hemophilia patients with inhibitors.



Gene_expression (expect) of PEGLip-FVIII associated with coagulation disorder
19) Confidence 0.62 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.40 Pain Relevance 0
Since FVIII and FVIIa are already present on the platelets prior to activation, the coagulation cascade is more efficient.
Gene_expression (present) of FVIII in platelets
20) Confidence 0.62 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.41 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox